NCT06377852 2026-03-18
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
American Society of Clinical Oncology
Phase 3 Recruiting
Clinical Trials
12 trialsNCT02947685 2026-02-12
PATINA
Alliance Foundation Trials, LLC.
Phase 3 Active not recruiting
NCT02513394 2026-02-10
PALLAS
Alliance Foundation Trials, LLC.
Phase 3 Active not recruiting
NCT03079011 2025-11-18
PADA-1
UNICANCER
Phase 3 Completed
NCT07061717 2025-07-11
Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Not yet recruiting
NCT05207709 2025-04-29
HARMONIA
SOLTI Breast Cancer Research Group
Phase 3 Active not recruiting
NCT02028507 2024-09-25
PEARL
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT01864746 2023-12-12
PENELOPE-B
GBG Forschungs GmbH
Phase 3 Completed
NCT03447132 2023-03-10
SAFIA
International Cancer Research Group, United Arab Emirates
Phase 3 Completed
NCT03969121 2023-03-10
Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
Kyoto Breast Cancer Research Network
Phase 3 Completed
NCT05429684 2022-06-23
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown
NCT04047758 2021-07-20
Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer
Shengjing Hospital
Phase 3 Unknown